{"organizations": [], "uuid": "ea3262a2b72c8c9d23831836a5dabd6b81a951ed", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/10", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/08/business-wire-acceleron-announces-appointment-of-chief-commercial-officer.html", "country": "US", "domain_rank": 767, "title": "Acceleron Announces Appointment of Chief Commercial Officer", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.247, "site_type": "news", "published": "2018-02-09T00:01:00.000+02:00", "replies_count": 0, "uuid": "ea3262a2b72c8c9d23831836a5dabd6b81a951ed"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/08/business-wire-acceleron-announces-appointment-of-chief-commercial-officer.html", "ord_in_thread": 0, "title": "Acceleron Announces Appointment of Chief Commercial Officer", "locations": [], "entities": {"persons": [{"name": "sujay", "sentiment": "none"}, {"name": "sujay kango", "sentiment": "none"}, {"name": "habib dable", "sentiment": "none"}, {"name": "kango", "sentiment": "none"}], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "cambridge", "sentiment": "none"}], "organizations": [{"name": "acceleron", "sentiment": "negative"}, {"name": "acceleron pharma inc.", "sentiment": "negative"}, {"name": "infinity pharmaceuticals-abbvie", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of commercial industry leader, Sujay Kango as Chief Commercial Officer (CCO). He brings over 25 years of commercial leadership and expertise, in both biotechnology and large pharmaceutical companies. Throughout his career, Mr. Kango has led multiple global product launches, including Kyprolis ® and Remicade ® , built commercial teams, and also served in collaboration leadership roles for both the Onyx Pharmaceuticals-Bayer and Infinity Pharmaceuticals-AbbVie partnerships.\nThis press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180208005195/en/\nSujay Kango named Chief Commercial Officer, Acceleron Pharma Inc.\n“We’re pleased to welcome Sujay to our team as we accelerate the commercial planning for luspatercept,” commented Habib Dable, Chief Executive Officer of Acceleron. “Sujay’s valuable commercial and leadership experience will be instrumental as we transform Acceleron from a research and development organization into a fully integrated commercial biopharmaceutical company by driving luspatercept to market as a first-in-class chronic anemia therapy for patients with MDS and beta-thalassemia alongside our partner, Celgene.”\n“I am thrilled to join Acceleron during this exciting time as we plan for the potential launch of luspatercept,” said Sujay Kango, Chief Commercial Officer of Acceleron. “Patients with beta-thalassemia and MDS who suffer from chronic anemia are in need of new treatments to reduce their disease burden and red blood cell transfusion dependence. I look forward to working together with our partner to build a leading commercial organization to launch luspatercept and advance treatment choices for the benefit of thousands of patients.”\nMost recently at AbbVie, Mr. Kango served as the Vice President of Global Commercial Development for Oncology, prior to which he served as the Executive Vice President and Chief Commercial Officer at Infinity Pharmaceuticals. Mr. Kango also served as Vice President, Global Marketing, and Sales Operations at Onyx Pharmaceuticals, an Amgen subsidiary. Prior to Onyx, he held several leadership positions including Vice President Sales and Marketing-Oncology at Merck & Co., Global Commercial Leader-Procrit ® /Eprex ® at Ortho-Biotech, and various sales and marketing positions at Schering-Plough. Mr. Kango earned a B.S. in Microbiology and an MBA from McNeese State University.\nAbout Acceleron\nAcceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.\nAcceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept planned in pulmonary arterial hypertension.\nFor more information, please visit www.acceleronpharma.com/ . Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn .\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180208005195/en/\nAcceleron Pharma Inc.\nTodd James, IRC, 617-649-9393\nVice President, Investor Relations and Corporate Communications\nor\nCandice Ellis, 617-649-9226\nManager, Investor Relations and Corporate Communications\nor\nMedia:\nBMC Communications\nBrad Miles, 646-513-3125\nSource: Acceleron Pharma", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FAcceleronPharma&esheet=51755293&newsitemid=20180208005195&lan=en-US&anchor=%40AcceleronPharma&index=2&md5=a1f100c7876ba5de83da6fc8ae6616cb", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.acceleronpharma.com%2F&esheet=51755293&newsitemid=20180208005195&lan=en-US&anchor=www.acceleronpharma.com%2F&index=1&md5=8da7db4ca53f0766c7b71f66b1f2d483", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Facceleron-pharma&esheet=51755293&newsitemid=20180208005195&lan=en-US&anchor=LinkedIn&index=3&md5=217fce56ed5928a4fc65f1e31a58dfdc", "http://www.businesswire.com/news/home/20180208005195/en/"], "published": "2018-02-09T00:01:00.000+02:00", "crawled": "2018-02-09T02:01:55.013+02:00", "highlightTitle": ""}